Palleon Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $100M

  • Investors
  • 8

Palleon Pharmaceuticals General Information

Description

Developer of therapeutics designed to offer glycol-immune checkpoint inhibitors to treat cancer. The company's therapeutics are integrated through insights into the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, enabling physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.

Contact Information

Formerly Known As
Palleon Pharma
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 266 Second Avenue
  • Waltham, MA 02451
  • United States
+1 (857)
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Corporate Office
  • 266 Second Avenue
  • Waltham, MA 02451
  • United States
+1 (857)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Palleon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 16-Sep-2020 $100M Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 04-Oct-2017 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Clinical Trials - Phase 2
To view Palleon Pharmaceuticals’s complete valuation and funding history, request access »

Palleon Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Palleon Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Palleon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutics designed to offer glycol-immune checkpoint inhibitors to treat cancer. The company's therapeut
Pharmaceuticals
Waltham, MA
30 As of 2024

Gaithersburg, MD
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Palleon Pharmaceuticals Competitors (13)

One of Palleon Pharmaceuticals’s 13 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
Lycia Therapeutics Venture Capital-Backed South San Francisco, CA
Pyxis Oncology Formerly VC-backed Boston, MA
IFM Therapeutics Venture Capital-Backed Boston, MA
Glycotope Formerly VC-backed Berlin, Germany
You’re viewing 5 of 13 competitors. Get the full list »

Palleon Pharmaceuticals Patents

Palleon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022257052-A1 Anti-inflammatory siglec proteins and methods of making and using same Pending 16-Apr-2021
CA-3215280-A1 Anti-inflammatory siglec proteins and methods of making and using same Pending 16-Apr-2021
EP-4323378-A2 Anti-inflammatory siglec proteins and methods of making and using same Pending 16-Apr-2021
EP-4323378-A4 Anti-inflammatory siglec proteins and methods of making and using same Pending 16-Apr-2021
US-20240156979-A1 Anti-inflammatory siglec proteins and methods of making and using same Pending 16-Apr-2021 A61K47/6811
To view Palleon Pharmaceuticals’s complete patent history, request access »

Palleon Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Palleon Pharmaceuticals Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Citadel Enterprise Americas Hedge Fund Minority
Matrix Capital Management Hedge Fund Minority
Surveyor Capital Hedge Fund Minority
AbbVie Ventures Corporate Venture Capital Minority
Pfizer Ventures Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Palleon Pharmaceuticals FAQs

  • When was Palleon Pharmaceuticals founded?

    Palleon Pharmaceuticals was founded in 2015.

  • Where is Palleon Pharmaceuticals headquartered?

    Palleon Pharmaceuticals is headquartered in Waltham, MA.

  • What is the size of Palleon Pharmaceuticals?

    Palleon Pharmaceuticals has 30 total employees.

  • What industry is Palleon Pharmaceuticals in?

    Palleon Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Palleon Pharmaceuticals a private or public company?

    Palleon Pharmaceuticals is a Private company.

  • What is the current valuation of Palleon Pharmaceuticals?

    The current valuation of Palleon Pharmaceuticals is .

  • What is Palleon Pharmaceuticals’s current revenue?

    The current revenue for Palleon Pharmaceuticals is .

  • How much funding has Palleon Pharmaceuticals raised over time?

    Palleon Pharmaceuticals has raised $148M.

  • Who are Palleon Pharmaceuticals’s investors?

    Citadel Enterprise Americas, Matrix Capital Management, Surveyor Capital, AbbVie Ventures, and Pfizer Ventures are 5 of 8 investors who have invested in Palleon Pharmaceuticals.

  • Who are Palleon Pharmaceuticals’s competitors?

    NexImmune, Lycia Therapeutics, Pyxis Oncology, IFM Therapeutics, and Glycotope are some of the 13 competitors of Palleon Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »